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ABSTRACT
Nanoparticles (NPs)-hydrogel composite (nanogels) have yielded a surge in the design and development of novel drug delivery systems for the 
treatment of many ailments, including periodontal disease. The recent innovations in nanotechnological drug carrier systems seem promising, as 
it provides a means to improve the bioavailability of poorly soluble drugs, formulations of controlled and targeted drug delivery systems, and drug 
release control based on the stimuli response, among others. Several polymeric NPs-hydrogel coformulations have been investigated during the 
last few years, mostly using synthetic and natural polymers. Some of the results and rewards achieved from these novel approaches are the use of 
bioadhesive polymers to achieve prolonged drug release, the increment of intra-pocket drug penetration, the enhancement of mechanical properties 
using chemical crosslinkers, and the possibility of loading multiple drugs in a unit delivery system. Furthermore, these nanotechnological advances 
have also shown that NPs possess great potential as drug carriers in periodontal disease treatment. The future utilization of these advantages will 
significantly improve dental care. The coformulation of NPs-hydrogel composite will yield additional benefits that are much greater than ordinary 
NPs or hydrogels in delivering of drug into the periodontal pockets. The aim of this review article is to summarize updates on the current and future 
nanotechnological approaches that are being investigated for the treatment of periodontitis, with particular attention to the nanogels, and to identify 
arenas which its exploration might lead to the development of effective intra-pocket drug delivery systems for the treatment of periodontal diseases. 
The review also provides brief applications of nanogels in the management of other diseases.
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INTRODUCTION
Periodontitis is a dental inflammatory disorder affecting the 
surrounding structures of the teeth (periodontium). The disease 
is characterized by inflammation and destruction of the teeth’s 
surrounding and supporting tissues, i.e., periodontal ligament (PDL), 
gum, alveolar bone, and cementum which usually occur as a result of 
anaerobic gram-negative bacterial invasion of the teeth [1].
A diagrammatical comparison of healthy and diseased tooth is depicted 
in Fig. 1. In the early stage of periodontitis, microorganisms adhere 
and multiply on the tooth’s surfaces which lead to the deposition of 
plaque and calculus. In the late stage of the disease, the collagen which 
supports the periodontium will be degraded; the gingival epithelium 
will shift against the tooth surface, and significant resorption of alveolar 
bone occurs resulting in the formation of a periodontal pocket [2]. If 
not properly treated, the consequence of that, along with the body’s 
over-aggressive immune response against the microbes would lead to 
the destruction of the periodontium and hence loosening and loss of 
teeth [3,4].
Delivering therapeutic agents to the periodontal pocket (target site) has 
been a major hurdle in the treatment of periodontitis. Most conventional 
local drug delivery systems have demonstrated poor results following 
their administration, due to poor penetration of the junctional 
epithelium (a circular arrangement of epithelial cells occurring at 
the base of the gingival sulcus and attached to both the tooth and 
the subepithelial connective tissue) [5]. Systemic antibiotics are now 
seldom used for the treatment periodontitis because of drawbacks such 
as gastrointestinal intolerance, rapid decline of antibiotic concentration 
in the plasma to subtherapeutic levels, inadequate antibiotic 
concentration at the site of the periodontal pocket, development of 
microbial resistance, and hypersensitivity [2]. Similarly, conventional 
local drug delivery systems are characterized by limited effectiveness, 
poor biodistribution, and lack of selectivity [6]. These drawbacks have 
drawn researchers’ interest in the development of new efficacious local 
drug delivery systems for the treatment of periodontitis.
An important positive outcome comes through recent advancement 
and innovations in nanotechnology, whereby nanotechnology-based 
colloidal drug carriers could be used to provide site-specific or targeted 
drug delivery, combined with optimal drug release profiles. Studies 
have shown that NPs may be a potential carrier system for the delivery 
of active substances to the periodontal pocket [7]. The incorporation 
of NPs into polymeric hydrogels has resulted in another interestingly 
novel class of dosage form that is called nanoparticles (NPs)-hydrogel 
coformulation (nanogels).
Nanogel delivery systems (Fig. 2) have attracted attention in recent 
years as one of the most promising nanoparticulate drug delivery 
systems owing to their unique potentials of yielding beneficial features 
of NPs (smaller size, site specificity, high stability, and high carrier 
capacity) and that of hydrogel system (i.e., hydrophilicity and extremely 
high water content) in a unit delivery system.
The aim of this review article is to acquaint the researchers, formulation 
scientist, and health-care providers, with the updates on the current 
and future nanotechnological approaches that are being investigated 
for the treatment of periodontitis and other ailments, with particular 
attention to nanogel delivery systems, owing to its unique potentials 
of achieving multidrug therapy and providing beneficial characteristics 
of NPs and that of hydrogel system in a unit delivery system. The 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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review also aims to identify areas where further research may lead to 
an effective development of intra-pocket drug delivery systems for the 
treatment for periodontitis.
NANOTECHNOLOGY IN DISEASE THERAPY
A significant number of locally administered drug delivering devices 
have been investigated and proposed over the last three decades 
(Table 1), but the restriction in accessing the periodontal pocket due 
to the complexity in anatomy of the root and the contours of the lesion 
which leads to poor penetration of junctional epithelium by some 
of these systems has limited their effectiveness in the treatment of 
periodontitis.
However, nanotechnology may revolutionize preventive, diagnostic, 
and restorative dentistry by providing nanosized materials that could 
effectively treat many dental disorders including periodontitis [34,35]. 
Several polymeric NPs-hydrogel coformulations have been proposed in 
the recent time, using both natural and synthetic polymers and these 
comes with a lot of advantages (Table 2) over the conventional drug 
delivery systems. Researchers have studied the transport of NPs through 
the junctional epithelium and reported that NPs can be a potential 
intra-pocket carrier system for the delivery of active substances to the 
periodontal pocket [7].
Nanogels in periodontitis
The potentials of nanogel delivery systems have been ascertained 
by many researchers in recent times. It has been reported that 
nanocomposite biocompatible hydrogels could be used as a model 
system for in situ local drug delivery devices for the treatment of 
periodontal diseases. Researchers have developed nanogels consisting 
of NPs and matrix gel loaded with chlorhexidine for antibacterial 
effect. They prepared NPs by free radical initiated copolymerization 
of the monomers and then used the same monomers to prepare 
crosslinked matrices by photopolymerization. Finally, they developed 
nanogels by blending the NPs, monomers, and drug in an aqueous 
solution and then crosslinked it by photopolymerization. This 
integrated gel system demonstrated distinct advantages compared 
to simple NPs or hydrogels as a delivery system, and hence, provides 
the chance of flexible intra-pocket drug delivery in periodontal 
disease treatment [41].
The PDL cells are essential factors that serve an important role in the 
regeneration of periodontal tissue, and there is a significant number 
of investigations that have been carried out to establish and validate 
its key characteristic features and functions [42]. The recent studies 
that have been carried out to reverse the periodontal degeneration 
(a condition that occurs as a result of severe periodontitis) using the 
transplantation of PDL cells have shown promising outcomes [43,44]. 
To verify the process of regeneration, Fukui et al. investigated whether 
cholesterol-bearing pullulan modified with amino groups (CHPNH2) 
nanogels could be used as a carrier to introduce quantum dots 
(QDs) into the PDL cells that were obtained from a primary culture. 
The CHPNH2 nanogels make complexes with QDs that resulted in 
monodisperse hybrid NPs, and it was able to be delivered into live cells 
by endocytosis, in significant quantity. The CHPNH2 nanogels were 
found to be useful as a carrier to introduce QDs into PDL cells under 
culture, and it demonstrated feasibility for further characterization of 
PDL cells as well as investigation of regenerative processes. This feature 
further demonstrates the capacity of nanogels system in periodontal 
therapy [45].
In another related research conducted by Popa et al., chitosan gel 
containing two antibacterial drugs (tetracycline hydrochloride and 
metronidazole benzoate) were fabricated for local intra-pocket drug 
delivery for the treatment of periodontal disease. Based on the kinetic 
release data and the rheological studies conducted on the periodontal 
gels, the researchers concluded that 3% w/w concentration of chitosan 
could offer a base for an optimum modulation in drug dose and its gels 
are efficient in local treatment of periodontal disease [26].
Similarly, doxycycline nanoliposome slow-release gel was evaluated 
for therapeutic effects on an established rat model of periodontitis. 
The biocompatibility of the system was examined by oral perfusion 
of the sample gel for a prolonged observation. The results reveal that 
doxycycline nanogel exhibit excellent biocompatibility from weight 
measure and tissue section evaluation. Furthermore, the NPs-hydrogel 
composite system demonstrates ability to improve the periodontitis 
condition of the rats with periodontitis defects [46].
To demonstrate the suitability and effectiveness of nanocomposite 
in repelling periodontal pathogens, a team of researchers 
developed a bioactive nanocomposite for Class V restorations with 
a combination of protein-repellent and antibacterial capabilities to 
combat periodontal biofilms. They fabricated resin which consists 
of ethoxylated bisphenol A dimethacrylate and pyromellitic glycerol 
dimethacrylate. Then, 2-methacryloyloxyethyl phosphorylcholine 
(MPC), dimethylaminohexadecyl methacrylate (DMAHDM), and 
NPs of amorphous calcium phosphate were incorporated into 
the previously made resin. The mechanical properties of the 
nanocomposite were similar to those of a commercial composite 
used in Class V restorations. The composite with 3% DMAHDM 
showed a strong antibacterial capability. The researchers concluded 
that the use of dual agents, i.e., 3% DMAHDM and 3% MPC, in the 
nanocomposite yielded a significant reduction in periodontal 
microbial biofilm growth, metabolic activity, and polysaccharide 
production. Hence, this novel nanocomposite is a promising device 
for Class V restorations to inhibit periodontal pathogens and for the 
treatment of periodontitis [47].
Fig. 1:  A comparison between healthy and diseased tooth. 
Periodontal pocket has developed on the diseased tooth
Fig. 2: Schematic illustration of nanoparticles-hydrogel 
coformulation (nanogels) in 3D [8]
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Nanogels in life-threatening diseases
Nanotechnological innovation in drug delivery is not limited to 
revolutionizing dental therapeutics alone but extends to many other 
fields of disease treatment (Table 3). Studies have shown that through 
nanotechnological techniques, there are possibilities of developing 
nanogel delivery systems whereby two drugs are loaded in a unit 
delivery system. Mark Tibbitt of Massachusetts Institute of Technology, 
USA and coresearchers carried out a study, in which two drugs were 
loaded in an nanogels. They developed polyethylene glycol-poly lactic 
acid NPs which were suited to carry hydrophobic small-molecule drug. 
On the other hand, they made a gel with a cellulose polymer suited to 
carry hydrophilic drug and then mixed the two components together 
which resulted in nanogels. They concluded that the research could be a 
potential model for delivering two different drugs at the same time, for 
the treatment of certain diseases, such as macular degeneration, cancer, 
and heart disease [48].
In another study, hydrogel-NPs with thermoresponsive properties 
were prepared and characterized. Inverse emulsion polymerization 
method was used in its development by crosslinking of acrylate 
derivatives of poly (ethylene glycol) and poly (ethylene glycol)-bl-
poly (propylene glycol)-blpoly (ethylene glycol) copolymers, also 
Table 1: Some investigated localized drug delivery system for the treatment of periodontal disease
Type of delivery system Drug (s)/Active agent (s) Polymer (s) References





Nanoparticles Metronidazole benzoate Thiolated chitosan-poly (methacrylic acid) [14]
Minocycline PLGA [15]
Triclosan Cellulose acetate phthalate and PLGA [7]
Triclosan PCL [5]
Minocycline PEG-PLA [16]
Zinc oxide and titanium dioxide Polysaccharide [17]
Films Ciprofloxacin and diclofenac Chitosan [18]
Chlorhexidine Ethyl cellulose [19]
Metronidazole Chitosan and PCL [20]
Metronidazole Ethyl cellulose - eudragit RS100 [21]
Chips Chlorhexidine Cross-linked hydrolyzed gelatin and glycerin [22]
Chlorhexidine PLGA [13]
Strips Chlorhexidine Acrylic polymer [23]
Metronidazole Hydroxypropyl cellulose [24]
Doxycycline Hydroxypropylmethylcellulose and methylcellulose [25]
Gels Tetracycline HCl and metronidazole benzoate Chitosan [26]
Metronidazole Chitosan [27]
Fibers Tetracycline PCL and cellulose acetate propionate [28]
Chlorhexidine Cellulose acetate [29]
Wafers Benzylpenicillin and tetracycline PLGA and ethyl cellulose [30]
Dendrimers Triclosan Polyamidoamine [31]
Implant Secnidazole and/or doxycycline PLA and PLGA [32]
Micelles Triclosan Micelles of poloxamine T1107 [33]
PLGA: Poly (dl‑lactic‑co‑glycolic acid), PLA: Poly lactic acid, PCL: Poly‑ε‑caprolactone, HCl: Hydrochloric acid
Table 2: Important applications of nanogel drug delivery systems [36-40]
•  Through the nanogels, multiple drugs can be incorporated and delivered to the targeted site even without chemical cross‑linkage. This is highly 
desirable in order to maintain the original drug activity
•  The nanogel systems can be suitably fabricated for various routes of administration such as oral cavity which include periodontal area, 
parenteral, intra-ocular and nasal cavity
• The nanogels provide opportunity for designing both passive and active targeting because of its surface nature and molecular size
• It also possesses high degree of drug loading, extreme high water content (hydrophilicity), flexibility in size as well as surface electrical charge
• Ease of production and handling, availability of raw materials for fabrication, and remarkable biocompatibility
•  Nanogels can be formulated with site‑specific targeting that can be achieved through linking ligands to the surface of nanoparticles embedded in 
it and consequently might enhance the solubility and pharmacokinetics of the conjugated drug molecules
Table 3: Summary of some nanoparticles-hydrogel composite drug delivery systems designed for various diseases
System Loaded active agent (s)/
drug (s)
Polymer (s) Method of preparation Targeted 
disease (s)
References
Topical nanogels Acitretin and aloe-emodin Chitin Regeneration chemistry method Psoriasis [51]










Self-crosslinking Ovarian cancer [54]
Topical nanogels Temoporfin Peptide conjugates Automated solid-phase peptide 
synthesis through peptide synthesizer
Skin cancer [55]
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known as Pluronics®. These synthesized hydrogel NPs were of size 
range of 100-500 nm and were found to be stable. The nanogels were 
fabricated with both hydrophilic and hydrophobic polymers to enable 
the accommodation of poorly water soluble active agents through 
hydrophobic interactions, and it has been determined to be potential 
carriers for drug delivery in cancer treatment [49].
To enhance the oral bioavailability of myricetin (a natural antioxidant 
flavonol identified to have a variety of therapeutic applications), a 
novel chitosan-based nanogels were comprehensively developed 
and evaluated. The formulated myricetin-loaded nanogels were of 
100-300 nm particle sizes range, and it displayed sol-gel transitions 
when exposed to physiological temperatures. The nanogels swelled 
in pH 6.8 and pH 7.4 buffers and were easily eroded in acidic buffer 
solutions (pH 1.2 and pH 4.5). The nanogel systems was able to release 
the loaded drugs moderately through a Fickian mechanism, and the 
oral bioavailability of myricetin in rats was improved by the developed 
novel nanogels delivery system [39].
A novel nanogels loaded with an anticancer agent (5-fluorouridine) 
of poly‑α, β‑polyasparthydrazide has been developed by reverse 
microemulsion technique with redox-responsive release mechanism. 
The smart nanogels had a NP size (~200 nm), a polyamino acid 
structure, a high drug loading of more than 20%. The nanogels was 
prepared by crossing‑link reaction of poly‑α, β‑polyasparthydrazide 
chains and 3,3’-dithiodipropionic acid through redox-responsive chain 
network. The developed system has good control of drug release profile 
and it showed excellent redox-responsibility and low cytotoxicity. 
These confirm it applicability as a potential controlled-release carrier 
for a redox-responsive tumor-targeting delivery of the anticancer agent 
5-fluorouridine [50].
FUTURE DIRECTIONS
Although the effort toward treating periodontal diseases has led to 
the advent of some successful delivery devices, there is still need for 
collective efforts to exploit more benefits in the NPs-based delivery 
system arena so that effective treatment could be achieved. Fig. 3 
classifies various current and future strategies for the treatment of 
periodontitis. The current approaches suffer from disadvantages such 
as limited effectiveness, poor biodistribution, short residence time, and 
lack of selectivity.
Therefore, the development of intra-pocket nanoparticulate delivery 
system with bioadhesive, biocompatible, and biodegradable polymer(s) 
that can provide targeted and controlled drug release would be highly 
desirable. The future research should focus on the use of bioadhesive 
polymers to enhance the residence time of the periodontal delivery 
systems. These future approaches should be able to make optimum 
contact with the mucosal surfaces in the periodontium and should 
prolong the residence time at the targeted site (i.e., in periodontal 
pocket) and should also intensify contact with the junctional epithelium 
so as to enhance the epithelial transport of poorly absorbable drugs. The 
use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment 
of periodontal disease seems to be feasible as research has shown that 
it may reduce gingivitis and slow progression of the disease [56].
Roles of nanogels in the future
Nanogels are expected to play a significant role in the future 
management of periodontitis, owing to its unique potential of 
achieving multidrug therapy and providing beneficial characteristics 
of both NPs and that of hydrogel systems, such as bioadhesiveness and 
biocompatibility (which could be imparted by the polymers) [57], the 
ability to encapsulate large amounts of drug(s) within its matrix, the 
high stability in aqueous medium, and the feature of releasing drugs in 
a controlled manner.
The future nanogels drug delivery innovations are focusing on drug 
release control based on stimuli responses. These nanogels with the 
prefix “smart” should be able to sense the changes in its surroundings 
and regulate the drug release profile accordingly. The invention of such 
systems may have profound potential applications, especially for drugs 
with narrow index or those with severe side effects [37]. Smart nanogels 
should be able to suitably react to certain environmental stimuli with 
instantaneous feedback when such specific stimuli signals are detected 
from stimulus. Studies have already proved that nanogels generally 
demonstrated rapid response compared to the conventional hydrogel 
particles [58]. These features will further qualify the use of nanogels in 
designing suitable drug delivery systems for various ailments including 
periodontitis. The initial investigations show that nanogels can changes 
it physical, chemical, electrical, and/or optical properties in response to 
a specific stimulus in its surrounding.







There is no doubt that nanogel drug delivery systems will play a vital role 
in future drug delivery systems not only for periodontitis but for a lot of 
other diseases that affect the human race. Investigations are underway 
for more exploitation, and some researchers had already reported 
applicability of these novel systems in the treatment of various illnesses 
as summarized in Table 3. The features and flexibility which nanogels 
provided has led to the opening of new horizons for nanotechnology-
based drug delivery systems for the treatment of diseases, hence, it 
will be of great significance in the future nanoparticulate drug delivery 
systems.
CONCLUSION
The recent developments in nanomaterials and nanotechnology have 
provided promising opportunities for the effective management of 
periodontitis. Some of the excellent results and rewards achievable 
from these novel approaches are the use of bioadhesive polymers to 
achieve prolonged drug release, the increment of intra-pocket drug 
penetration, the enhancement of mechanical properties using chemical 
crosslinkers, and the possibility of loading multiple drugs in a unit 
delivery system. Furthermore, the advent of smart-nanogel innovations 
whereby drug release may be control by stimuli responses gives 
additional promising opportunities in achieving optimum therapeutic 
effect. The future utilization of these advantages will significantly 
improve dental care. The coformulation of nanoparticles-hydrogel 
composite showed additional advantages compared to simple NPs or 
hydrogels as local intra-pocket drug delivery systems. These rewards 
will pave the way for further research opportunities in drug delivery 
system development, thus advancing dental therapeutics.
Fig. 3: Classification of various current and future nanoparticulate 
drug delivery systems for the treatment of periodontitis
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